When initiating trazodone, what baseline liver function tests are required, how frequently should they be monitored, and how should the dose be adjusted in patients with liver disease or risk factors?

Trazodone and Liver Function Tests

No baseline liver function tests are required before initiating trazodone, and routine monitoring of LFTs is not recommended in the absence of clinical symptoms or risk factors for liver disease.

Baseline Testing

The FDA-approved labeling for trazodone does not mandate baseline liver function testing before initiation 1. However, clinical judgment should guide whether to obtain baseline LFTs in specific populations:

• Obtain baseline LFTs if:
  • History of hepatitis C or other chronic liver disease
  • HIV-positive status (particularly with hepatitis co-infection)
  • Active substance use disorder
  • Concurrent use of other hepatotoxic medications
  • Pre-existing liver dysfunction

This recommendation is informed by a case report demonstrating severe hepatotoxicity after only 4 days of trazodone 200 mg/day in an HIV-positive patient with hepatitis C 2. The patient developed acute hepatitis and cholestasis, which resolved 10 days after discontinuation.

Monitoring Frequency

Routine periodic monitoring is not indicated. Instead, monitor LFTs only if:

• Patient develops symptoms suggestive of hepatotoxicity (fatigue, nausea, vomiting, right upper quadrant pain, jaundice)
• Patient has baseline liver disease and develops new symptoms
• Concurrent hepatotoxic medications are added to the regimen

The mechanism of trazodone hepatotoxicity involves formation of triazolopropionic aldehyde (M1), a reactive metabolite that conjugates with endogenous amines and depletes glutathione, leading to hepatocellular injury 3.

Dose Adjustment in Liver Disease

For patients with known liver dysfunction:

• Start at lower doses: 25-50 mg daily (rather than standard 150 mg)
• Titrate more slowly: Increase by 25-50 mg increments every 5-7 days based on tolerability
• Target lower maximum doses: Consider 150-200 mg as upper limit rather than 300-400 mg

The rationale is that trazodone undergoes extensive hepatic metabolism via CYP3A4, and liver dysfunction significantly affects drug clearance 4. Patients with elevated baseline transaminases or cirrhosis have impaired drug metabolism, increasing risk of both therapeutic and toxic plasma concentrations 5.

Clinical Thresholds for Action

If monitoring LFTs in at-risk patients, use these thresholds adapted from DILI guidelines 6:

For patients with normal baseline ALT:

• ALT ≥5× ULN → Repeat testing in 2-5 days, evaluate alternative causes
• ALT ≥8× ULN → Discontinue trazodone immediately
• ALT ≥3× ULN + total bilirubin ≥2× ULN → Discontinue immediately (Hy's Law criteria)

For patients with elevated baseline ALT:

• ALT ≥3× baseline or ≥300 U/L → Repeat testing, evaluate causes
• ALT ≥5× baseline or ≥500 U/L → Discontinue trazodone

Critical Pitfalls

1. Don't ignore early symptoms: Hepatotoxicity can occur within days, not just weeks to months 2
2. Multiple risk factors compound: HIV, hepatitis C, substance use, and polypharmacy create synergistic risk
3. CYP3A4 interactions matter: Strong inhibitors (ketoconazole, clarithromycin) increase trazodone exposure and hepatotoxicity risk 1
4. Age increases risk: Older patients have higher plasma concentrations at equivalent doses 5

Contraindications

Do not rechallenge with trazodone if patient previously experienced:

• Jaundice or elevated bilirubin with transaminase elevation
• Signs of hepatic decompensation
• Hypersensitivity features (rash, fever, eosinophilia)

These criteria align with DILI rechallenge guidelines that preclude rechallenge after severe hepatocellular injury 7.